Zanubrutinib

26 trials 16 recruiting LOncology

Filter these 26 trials by condition, phase, country and more.

Open in Search →

26 Registered trials

16 Recruiting

10 Completed trials

13 Sponsors

19 Countries

Phase III

Phase II/III

Phase II

Phase I/II

Phase III: 8 Phase II/III: 3 Phase II: 12 Phase I/II: 3

Oversight events:

2 urgent safety measures across 1 trial

View oversight register →

Indications tested

Mantle cell lymphoma 2 Marginal zone lymphoma recurrent 1 Waldenstrom´s macroglobulinaemia recurrent 1 Chronic lymphocytic leukaemia 1 Follicular lymphoma 1 Follicular lymphoma stage III 1 Marginal zone lymphoma 1 Splenic marginal zone lymphoma 1 Follicle centre lymphoma follicular grade I II III 1 Mantle cell lymphoma refractory 1 Richter's syndrome 1 Diffuse large B-cell lymphoma refractory 1

Sponsors using this IMP

BeOne Medicines AG 12 Ascentage Pharma Group Inc. 2 University Of Cologne 2 Association International Extranodal Lymphoma Study Group (IELSG) 1 Azienda Ospedaliera di Padova 1 Beigene Ltd. 1 Curis Inc. 1 Fondazione Gimema Franco Mandelli Onlus 1 Fondazione Italiana Linfomi Ets 1 Fundacion PETHEMA 1 Haemato Oncology Foundation For Adults Netherlands 1 Lymphoma Academic Research Organisation 1

All trials — page 2

26 total

A Phase 3 Study of Zanubrutinib (BGB-3111) Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocyt… Ended

2023-509976-40-00 Phase III 8 countries BeOne Medicines AG
A Phase 2 Study combining BGB-3111 with Obinutuzumab compared with Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma Ended

2023-509975-17-00 Phase II 5 countries Beigene Ltd.

Showing 25–26 of 26 trials

← All drugs A–Z